DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Information source: SCRI Development Innovations, LLC
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Metastatic Melanoma

Intervention: Paclitaxel (Drug); Carboplatin (Drug); Everolimus (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: SCRI Development Innovations, LLC

Official(s) and/or principal investigator(s):
John D. Hainsworth, M.D., Study Chair, Affiliation: SCRI Development Innovations, LLC


Based on data demonstrating synergy between paclitaxel and mammalian target of rapamycin (mTOR) inhibition, the investigators propose that the addition of everolimus to paclitaxel with carboplatin should lead to improvements in efficacy as measured by progression-free survival and response rate.

Clinical Details

Official title: A Phase II Study of Everolimus in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Progression-free Survival (PFS)

Secondary outcome:

Overall Survival (OS)

Objective Response Rate (ORR)


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria: 1. Histologically confirmed metastatic melanoma. 2. Stage III or IV disease that is not amenable to resection. 3. Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1. 1. If the patient has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation. 4. ECOG Performance Status of 0 or 1. 5. Life expectancy ≥12 weeks. 6. No prior cytotoxic chemotherapy or targeted therapy. Immunotherapy is allowed (i. e., interleukin-2 or interferon). 7. Adequate hematological function:

- absolute neutrophil count (ANC) ≥1500/µL and

- platelets ≥100,000/µL and

- hemoglobin >9 g/dL

8. Adequate renal function: serum creatinine ≤2. 0 mg/dL or calculated (measured) GFR ≥50 mL/min. 9. Adequate hepatic function:

- serum bilirubin ≤1. 5 x institutional upper limit of normal (ULN);

- aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2. 5 × ULN,

or ≤5 × ULN in patients with documented liver metastases. 10. Normal PT, INR. Patients on coumadin anticoagulation are eligible if they are on a stable dose, with an INR in the therapeutic range. 11. Fasting serum cholesterol ≤300 mg/dL OR ≤7. 75 mmol/L AND fasting triglycerides ≤ 2. 5 x ULN. NOTE: In case one or both of these thresholds are exceeded, the patient can be included after initiation of appropriate lipid lowering medication. 12. Age ≥18 years. 13. Ability to swallow whole pills. 14. Patient must be accessible for treatment and follow-up. 15. Patients must be able to understand the investigational nature of this study and give written informed consent prior to study entry. Exclusion Criteria: 1. Previous treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus), paclitaxel, or carboplatin. 2. Treatment with any investigational agent ≤4 weeks of protocol treatment. 3. Patients currently receiving anticancer therapies or who have received anticancer therapies ≤3 weeks of the start of the study drug (including radiation therapy, immunotherapy). 4. Patients, who have had a major surgery or significant traumatic injury ≤4 weeks of start of study drug or patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia). 5. Patients receiving chronic, systemic treatment with corticosteroids (dose >10 mg daily of methylprednisolone or equivalent) or other immunosuppressive agents. Topical or inhaled steroids are allowed. 6. Immunization with attenuated live vaccine ≤1 week of study or anytime during study treatment period. 7. Patients with active brain metastases are ineligible. Patients with treated brain metastases are eligible if (1) radiation therapy was completed ≥4 weeks prior to study entry; (2) surgery was completed ≥4 weeks prior to study entry; (3) follow-up scan shows no disease progression; and (4) patient does not require steroids. 8. Any severe and/or uncontrolled medical conditions or other conditions that could affect participation in the study such as:

- severely impaired lung function defined as a DLCO ≤50% of the normal

predicted value and/or O2 saturation ≤88% at rest on room air.

- symptomatic congestive heart failure of New York Heart Association Class III or


- unstable angina pectoris, symptomatic congestive heart failure, myocardial

infarction ≤6 months of start of study drug, serious uncontrolled cardiac arrhythmia or any other clinically significant disease.

- uncontrolled diabetes as defined by fasting serum glucose >1. 5 x ULN.

- active (acute or chronic) uncontrolled severe infections.

- liver disease such as cirrhosis, chronic active hepatitis or chronic persistent

hepatitis. 9. Active, bleeding diathesis. 10. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of everolimus (e. g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection). 11. A known history of human immunodeficiency virus (HIV) seropositivity. 12. Known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients. 13. Use of St. John's Wort is prohibited. Drugs or substances (e. g., grapefruits, star fruits, seville oranges, and their juices and products), known to be inhibitors or inducers of the isoenzyme CYP3A4 should be avoided. Co-administration with substrates, inducers, or inhibitors of P glycoprotein should also be avoided. 14. Female patients who are pregnant or breastfeeding or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes. Hormonal contraceptives are not acceptable as a sole method of contraception. (Women of childbearing potential [WOCBP] must have a negative urine or serum pregnancy test within 7 days prior to administration of everolimus.) WOCBP should continue to use effective contraception for 8 weeks after ending everolimus treatment. 15. Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin. 16. History of noncompliance to medical regimens. Patients unwilling to, or unable to, comply with the protocol. 17. History of any other disease, physical examination finding, or clinical laboratory finding that gives reasonable suspicion of a disease or a condition that may render the patient at high risk for treatment complications using these agents.

Locations and Contacts

Florida Cancer Specialists, Fort Myers, Florida 33901, United States

Northeast Georgia Medical Center, Gainesville, Georgia 30501, United States

Oncology Hematology of SW Indiana, Evansville, Indiana 47630, United States

Hematology Oncology Clinic, LLP, Baton Rouge, Louisiana 70809, United States

Center for Cancer and Blood Disorders, Bethesda, Maryland 20817, United States

Grand Rapids Oncology Program, Grand Rapids, Michigan 49503, United States

Research Medical Center, Kansas City, Missouri 64132, United States

Nebraska Methodist Cancer Center, Omaha, Nebraska 68114, United States

Oncology Hematology Care, Cincinnati, Ohio 45242, United States

Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee 37404, United States

Tennessee Oncology, PLLC, Nashville, Tennessee 37023, United States

Peninsula Cancer Institute, Newport News, Virginia 23601, United States

Additional Information

Starting date: February 2010
Last updated: February 10, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017